EGFR and colorectal carcinoma: The prognostic value of KRAS mutations in CRC remains controversial, even though KRAS mutations have been associated with a poor response to anti-EGFR antibody therapy in metastatic CRC (Karapetis et al, 2008; Bokemeyer et al, 2009; Van Cutsem et al, 2009).